PNC-27 for Dogs
PNC-27 (p53-derived HDM-2 binding peptide)
The short answer
There is no honest way to characterise PNC-27 as safe or unsafe for dogs, because no dog has been formally studied. All published evidence is in vitro and rodent. The mechanism is genuinely interesting and the preclinical selectivity data is real, but the gap between that and a canine safety profile is enormous. This belongs in the hands of a veterinary oncologist making a considered decision about a specific patient, not in a general protocol.
What it is and how it is thought to work
PNC-27 is a fragment derived from the p53 tumour suppressor protein. Laboratory research reports that it binds a protein called HDM-2 that sits on the surface of many cancer cells but not on healthy ones, and that this binding forms pores that rupture the cell. That selectivity is the appeal. It is important to be clear that this work is in cell culture and rodents — no dog has been formally studied.
Mechanism in clinical terms
Reported to bind membrane-bound HDM-2, overexpressed on the surface of transformed cells in vitro, forming pores that induce selective necrosis. Normal cells are reported to lack surface HDM-2 and to be spared in preclinical models. Intratumoral administration is likely most effective for accessible lesions. Level V evidence.
Canine dosing by weight class
Figures below are reported as they appear in the source literature. They are not recommendations, and dosing for an individual dog must be set by a veterinarian.
| Weight class | Reported dose | Frequency | Duration | Studied for |
|---|---|---|---|---|
| Small / toy breedunder 22 lb (10 kg) | 5-20 mg per dose | 2-3x weekly | 8-12+ weeks | Investigational oncology adjunct, veterinary supervision required |
| Medium breed22–77 lb (10–35 kg) | 10-70 mg per dose | 2-3x weekly | 8-12+ weeks | Investigational oncology adjunct, veterinary supervision required |
| Large / giant breedover 77 lb (35 kg) | 20-150 mg per dose | 2-3x weekly | 8-12+ weeks | Investigational oncology adjunct, veterinary supervision required |
Need a figure for a specific weight? Use the dose calculator, or see the weight-specific pages: small / toy breed, medium breed, large / giant breed.
Contraindications and warnings
Read these before anything else on the page.
⚠ No companion animal data exists
Every published finding on PNC-27 comes from cell culture or rodent models. There are no canine trials, no canine pharmacokinetics, and no canine safety data. This compound is included for completeness of the research landscape, not as a recommendation. It should only ever be considered under direct veterinary oncology supervision.
Example research protocol
A representative timeline drawn from the published literature, showing what is monitored and when. Any actual protocol should be set by the veterinarian managing the case.
- 1Week 1Staging and initiation
What owners observe
Photograph and measure every visible tumour before starting. Record appetite, energy, and pain behaviours. Mild injection-site tenderness is expected and transient.
Clinical monitoring
Full staging: imaging, CBC, chemistry panel. 0.5-2 mg/kg subcutaneously or intratumorally 2-3x weekly. Reported to bind membrane HDM-2 with selective necrosis in preclinical models.
- 2Weeks 4-6First assessment
What owners observe
A tumour may soften, shrink, or ulcerate. Ulceration reflects necrosis and can be a positive response rather than deterioration, but it needs veterinary assessment. Report any weight loss immediately.
Clinical monitoring
Re-image and compare dimensions. Tumour necrosis is the expected histological response. If combined with thymosin alpha-1, NK and CD8+ counts should be rising.
- 3Weeks 8-12+Ongoing assessment
What owners observe
Quality of life is the metric that governs the decision to continue. Sustained appetite, activity, and comfort indicate a positive course. Document weekly with photographs.
Clinical monitoring
Continue 2-3x weekly if responding. Full restaging at week 12. No cumulative toxicity reported at therapeutic doses in the available preclinical work.
What PNC-27 is investigated for
Common questions
Is PNC-27 safe for dogs?+
There is no honest way to characterise PNC-27 as safe or unsafe for dogs, because no dog has been formally studied. All published evidence is in vitro and rodent. The mechanism is genuinely interesting and the preclinical selectivity data is real, but the gap between that and a canine safety profile is enormous. This belongs in the hands of a veterinary oncologist making a considered decision about a specific patient, not in a general protocol.
How much PNC-27 should I give my dog?+
Reported doses vary by weight class. Small / toy breed (under 22 lb (10 kg)): 5-20 mg per dose, 2-3x weekly. Medium breed (22–77 lb (10–35 kg)): 10-70 mg per dose, 2-3x weekly. Large / giant breed (over 77 lb (35 kg)): 20-150 mg per dose, 2-3x weekly. These figures are reported as they appear in the source literature and are not recommendations — dosing for an individual dog must be set by a veterinarian who has examined the animal.
How is PNC-27 given to dogs?+
PNC-27 is administered by subcutaneous injection or intratumoral injection. See the injection guide and reconstitution guide for handling detail.
What is the evidence for PNC-27 in dogs?+
PNC-27 is graded as preliminary evidence on this site, drawing on 3 cited studies. PNC-27 is a fragment derived from the p53 tumour suppressor protein. Laboratory research reports that it binds a protein called HDM-2 that sits on the surface of many cancer cells but not on healthy ones, and that this binding forms pores that rupture the cell. That selectivity is the appeal. It is important to be clear that this work is in cell culture and rodents — no dog has been formally studied.
References
- 1.Sarafraz-Yazdi E, et al. Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes. PNAS, 2010. PMID 20080606
- 2.Sookraj KA, et al. The anti-cancer peptide PNC-27 induces tumor cell lysis as the intact peptide. Cancer Chemotherapy and Pharmacology, 2010. PMID 20182728
- 3.Davitt K, et al. The anti-cancer peptide PNC-27 induces necrosis in K562 leukemia cells. Annals of Clinical and Laboratory Science, 2014. PMID 25117093
Educational information — not veterinary medical advice
Everything on this page is compiled from published peer-reviewed literature for educational and research purposes. It does not establish a veterinarian-client-patient relationship (VCPR) and is not a substitute for veterinary examination and diagnosis. Most compounds described here are investigational or used off-label and are not FDA-approved for these purposes in dogs. Extralabel drug use in animals requires a valid VCPR and the direct supervision of a licensed veterinarian under AMDUCA (21 U.S.C. §360b). Dosing figures are reported as they appear in the source literature and are not recommendations.